GeneSight vs 23andMe: Pharmacogenomic Testing Compared
9 min read · Last updated: April 2026 · DecodeMyBio Editorial Team
If you've taken a 23andMe test and are now looking into pharmacogenomics, you've probably wondered: can my existing DNA data do what GeneSight does? The short answer is partially — and at a fraction of the cost. This page breaks down exactly how GeneSight and 23andMe-based pharmacogenomic analysis compare, so you can decide which approach fits your situation.
GeneSight is a clinical pharmacogenomic test ordered through your doctor. 23andMe is a consumer DNA test that wasn't built for pharmacogenomics — but its raw data contains many of the same genetic variants. Services like DecodeMyBio can analyze that raw data and produce pharmacogenomic reports mapped to published CPIC guidelines. The two approaches differ in cost, coverage, convenience, and clinical context.
Already have 23andMe or AncestryDNA data?
You can get pharmacogenomic analysis using data you already own — no new test, no provider order, no insurance billing. DecodeMyBio maps your raw data to published CPIC clinical guidelines across 19 genes and 150+ drug-gene interactions.
What Is GeneSight?
GeneSight is a clinical pharmacogenomic panel manufactured by Myriad Genetics. It analyzes 15 genes covering over 60 psychotropic medications and is designed specifically for psychiatric prescribing decisions. Key characteristics:
- Doctor-ordered: You cannot take GeneSight on your own. A prescribing clinician must order the test and interpret the results.
- Targeted sequencing: GeneSight uses laboratory methods that provide full allele coverage for the specific genes it tests, including rare variants and structural changes like gene deletions or duplications.
- Psychiatric focus: The report categorizes medications into "use as directed," "moderate gene-drug interaction," and "significant gene-drug interaction" bins using a proprietary algorithm.
- Cost: $330 self-pay. Medicare Part B typically covers it at $0. Commercial insurance coverage varies.
- Turnaround: Results typically available within 36 hours after the lab receives the sample.
For more on GeneSight pricing and insurance, see our GeneSight cost breakdown. For a broader look at alternatives, see GeneSight alternatives.
What Can 23andMe Data Tell You About Pharmacogenomics?
23andMe is a consumer DNA test that uses a genotyping chip to read approximately 600,000+ genetic variants across your genome. The chip was designed primarily for ancestry analysis and health traits — not pharmacogenomics. However, because pharmacogene variants are scattered across the genome, the 23andMe chip captures many of them as a byproduct.
When you download your 23andMe raw data file, that file contains genotype calls for hundreds of thousands of positions — including variants in key pharmacogenes like CYP2D6, CYP2C19, CYP2C9, VKORC1, and others. A raw data analysis service like DecodeMyBio extracts those pharmacogene variants, determines your metabolizer status for each gene, and maps the results to published CPIC clinical guidelines.
The key distinction: 23andMe tests a predefined set of tag SNPs for each gene. It does not sequence the full gene. This means it reliably identifies common alleles (which account for the vast majority of clinically relevant metabolizer phenotypes) but may miss rare or novel variants that full sequencing would detect.
Side-by-Side Comparison
Information sourced from each company's public materials as of April 2026. Verify current details directly with each provider.
| Feature | GeneSight | 23andMe + DecodeMyBio |
|---|---|---|
| Cost | $330 self-pay (insurance may cover) | $19–59 (if you already have 23andMe data) |
| Genes covered | 15 (full sequencing) | 19 (chip-based tag SNPs) |
| Ordering | Requires doctor order | Self-service upload |
| Turnaround time | ~36 hours after lab receipt | Instant (minutes) |
| Insurance | Medicare Part B: $0 typical. Commercial: varies. | Not applicable (but much cheaper out-of-pocket) |
| Accuracy | Full gene sequencing — detects rare alleles | Chip genotyping — >99% for tested variants |
| Report scope | Single psychiatric panel | 6 focused reports (psychiatric, pain, nutrition, cannabis, celiac, medication safety) |
| Guideline basis | Proprietary algorithm | Published CPIC guidelines |
| New DNA sample needed | Yes (cheek swab) | No (uses existing data) |
When GeneSight Is the Better Choice
GeneSight makes more sense in specific clinical situations where the depth of testing and the doctor-integrated workflow provide clear advantages:
- Insurance covers it: If your plan covers GeneSight (especially Medicare Part B at $0), the cost advantage of raw data analysis disappears.
- You need full allele coverage: For genes like CYP2D6, which has many rare alleles and structural variants (gene deletions, duplications), GeneSight's sequencing approach is more thorough than chip-based genotyping.
- Your doctor wants it: Some clinicians prefer a test they order themselves, with results delivered directly to their EHR. GeneSight integrates into that clinical workflow.
- Critical prescribing decisions: If you're making a high-stakes medication change (e.g., switching antidepressants after multiple failures), the more complete allele coverage of clinical testing may be worth the cost.
- You don't have existing DNA data: If you've never taken a consumer DNA test, GeneSight provides pharmacogenomic results without needing to buy a 23andMe kit first.
When 23andMe Data Analysis Is the Better Choice
Analyzing existing 23andMe data makes more sense when cost, convenience, or breadth of coverage matters most:
- You already have the data: Millions of people already have 23andMe or AncestryDNA results sitting unused. If that's you, pharmacogenomic analysis is available right now for a fraction of GeneSight's cost.
- Cost sensitivity: At $19–59 vs $330, the price difference is significant — especially if insurance won't cover GeneSight. For context, see our pharmacogenomic testing cost guide.
- Broader coverage: DecodeMyBio offers six report types — psychiatric, pain management, nutrition, cannabis, celiac, and medication safety — covering drug categories beyond psychiatry.
- Instant results: No waiting for a doctor appointment, cheek swab shipping, or lab processing. Upload your file and get results in minutes.
- Starting point for awareness: If you want to understand your pharmacogenomic profile before deciding whether clinical testing is needed, raw data analysis is a low-cost way to screen.
What About Accuracy?
This is the most important question, and it deserves a direct answer.
GeneSight uses targeted sequencing methods that provide comprehensive allele coverage for each gene it tests. This means it can detect rare alleles, structural variants (like CYP2D6 gene deletions and duplications), and novel mutations. For its 15 genes, GeneSight's coverage is thorough.
23andMe uses a genotyping chip that reads specific positions (tag SNPs) across the genome. For the variants it does test, the accuracy is very high — published validation studies show >99% concordance rates. The limitation is not accuracy of individual calls, but completeness of coverage. The chip tests the most common clinically relevant alleles but may miss rarer ones.
In practice: For the most common drug-gene interactions — the ones that affect the largest number of people — both approaches typically identify the same metabolizer status. The common alleles (e.g., CYP2D6 *3, *4, *5, *6, *41; CYP2C19 *2, *3, *17) are well-represented on consumer genotyping chips. Where the approaches diverge is in detecting rare alleles that affect a small percentage of the population.
For a fuller discussion of what consumer genotyping can and cannot detect, see our limitations page and methodology. If you want to understand how pharmacogenomics works, our learn section covers the fundamentals.
The Practical Decision
Most people searching "GeneSight vs 23andMe" fall into one of two groups:
- Group 1: Already have 23andMe data. If this is you, start with raw data analysis. It costs $19–59, takes minutes, and covers the most common drug-gene interactions. If the results flag something clinically significant or if your doctor wants confirmatory testing, you can pursue GeneSight afterward. You lose nothing by starting here.
- Group 2: No existing DNA data. If you haven't taken any DNA test, your decision depends on context. If your doctor recommends GeneSight and insurance covers it, that's the straightforward path. If you want broader insights beyond psychiatry (nutrition, pain, cannabis), a 23andMe kit ($99–199) plus DecodeMyBio analysis gives you more total coverage at a comparable or lower cost.
Either way, pharmacogenomic information is worth having. Studies consistently show that drug-gene interactions affect medication response in a meaningful percentage of the population. The question is not whether to get this information, but which path makes sense for your situation.
Already have 23andMe data? Get your pharmacogenomic report in minutes.
Upload your raw data file and see your metabolizer phenotypes mapped to CPIC guidelines across 19 genes and 150+ drug-gene interactions. No doctor visit, no insurance, no waiting.
Frequently Asked Questions
Can 23andMe data replace a GeneSight test?
Partially. 23andMe raw data contains many of the same pharmacogene variants that GeneSight tests. When analyzed through a service like DecodeMyBio, it can identify your metabolizer status for common drug-gene interactions. However, 23andMe uses a genotyping chip rather than full gene sequencing, so it may miss rare alleles. For most common variants, both approaches yield the same metabolizer classification.
How much does GeneSight cost compared to 23andMe analysis?
GeneSight costs $330 self-pay (may be covered by insurance). If you already have 23andMe data, DecodeMyBio's pharmacogenomic analysis costs $19–59 depending on the report — no insurance billing, no doctor visit required. See our pharmacogenomic testing cost guide for a broader price comparison.
Does GeneSight test more genes than 23andMe?
GeneSight tests 15 pharmacogenes with full sequencing coverage. 23andMe's chip contains variants across more pharmacogenes (DecodeMyBio analyzes 19), but uses tag SNPs rather than full sequencing. GeneSight has deeper per-gene coverage; 23andMe data analysis covers more genes with fewer variants per gene.
Is GeneSight more accurate than 23andMe for pharmacogenomics?
GeneSight uses targeted sequencing, which detects a broader range of alleles per gene including rare variants. 23andMe's chip is highly accurate (>99% concordance) for the variants it tests, but covers a predefined set. For the most clinically relevant common variants, both approaches typically produce the same metabolizer classification.
Can I show my 23andMe pharmacogenomic report to my doctor?
Yes. DecodeMyBio reports include a clinician pocket summary designed for healthcare provider review. The report presents your metabolizer phenotypes mapped to published CPIC guidelines with references that clinicians can use alongside their clinical judgment.